FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS

被引：0
作者：
Bellone, M. [1 ]
Pradelli, L. [1 ]
Sanfilippo, A. [1 ]
Caputo, A. [2 ]
Manevy, M. [3 ]
Zerilli, A. [4 ]
机构：
[1] AdRes HEOR, Turin, TO, Italy
[2] Roche Spa, Monza, Italy
[3] F Hoffmann La Roche Ltd, Delemont, Switzerland
[4] Roche Spa, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC113
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [41] FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
    Gao, Jennifer J.
    Osgood, Christy L.
    Gong, Yutao
    Zhang, Hui
    Bloomquist, Erik W.
    Jiang, Xiling
    Qiu, Junshan
    Yu, Jingyu
    Song, Pengfei
    Rahman, Nam Atiqur
    Chiu, Haw-Jyh
    Ricks, Tiffany K.
    Rizvi, Fatima
    Hou, Sherry
    Wilson, Willie
    Abukhdeir, Abde M.
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Pierce, William F.
    Bhatnagar, Vishal
    Kluetz, Paul G.
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2126 - 2129
  • [42] Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
    Jagosky, Megan
    Tan, Antoinette R.
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 393 - 407
  • [43] Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
    Dang, Chau T.
    Tolaney, Sara M.
    Riaz, Fauzia
    Tan, Antoinette R.
    Tkaczuk, Katherine H. R.
    Yu, Anthony Francis
    Liu, Jennifer
    Fung, Anita M.
    Yang, Anna
    Day, Bann-Mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Role of pertuzumab in the treatment of HER2-positive breast cancer
    Hubalek, Michael
    Brantner, Christine
    Marth, Christian
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 65 - 73
  • [45] Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC)
    Loi, S.
    Michiels, S.
    Salgado, R.
    Sirtaine, N.
    Jose, V.
    Fumagalli, D.
    Brown, D. N.
    Kellokumpu-Lehtinen, P-L
    Bono, P.
    Kataja, V.
    Desmedt, C.
    Piccart-Gebhart, M. J.
    Loibl, S.
    Untch, M.
    Denkert, C.
    Smyth, M. J.
    Joensuu, H.
    Sotiriou, C.
    CANCER RESEARCH, 2013, 73
  • [46] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [47] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Hogea, Alexandra
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Jackisch, Christian
    LANCET ONCOLOGY, 2021, 22 (01) : 85 - 97
  • [49] Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
    Cortes, Javier
    Ciruelos, Eva.
    Perez-Garcia, Jose
    Albanell, Joan
    Garcia-Estevez, Laura
    Ruiz-Borrego, Manuel
    Espinosa, Ruth
    Gallegos, Isabel
    Gonzalez, Santiago
    Alvarez, Isabel
    Llombart, Antonio
    CANCER TREATMENT REVIEWS, 2020, 83
  • [50] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
    Lopez-Vivanco, G.
    Salvador, J.
    Diez, R.
    Lopez, D.
    De Salas-Cansado, M.
    Navarro, B.
    De la Haba-Rodriguez, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12) : 1454 - 1461
12345